TheEdgeResearch
Home / Stocks / LTRN

Lantern Pharma Inc. (LTRN)

NASDAQ Healthcare Biotechnology
$0.24 ▼ -13.73%
Market Cap
$3.9M
Sector
Healthcare
Industry
Biotechnology
Beta
2.46
52-Wk Range
0.2286-4.34
CEO
Panna Sharma
Country
US
Currency
USD

Lantern Pharma Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Dallas, TX, US. The stock last traded at $0.24, down 13.73% on the session, giving a market capitalisation of $3.9M. On trailing twelve-month figures it carries a trailing P/E of -0.21, a net margin of 0.0%. Its beta of 2.46 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.21
Price / Sales
0.00
Price / Book
2.35
EV / EBITDA
0.27
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.03
Current ratio
1.49
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
16
IPO date
2020-06-11
Headquarters
Dallas, TX, US
About Lantern Pharma Inc.

Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.

Comparable companies

Lantern Pharma Inc. is most often compared with the following Healthcare names:

ANVSATNMBCABCALCELUTLVTXMAIARNXTRVPHTVRD
More research on LTRN
LTRN technical analysis LTRN TheEdge Score Compare against peers
Open full interactive analysis & DCF →